15 recruiting, 14 unknown, 13 completed, 8 active not recruiting. 17 Phase 1, 17 Phase 2, 10 Not applicable, 7 Phase 3, 2 Phase 4.
Follow Non-muscle Invasive Bladder Cancer: new trials by email Literature Review of Non-muscle Invasive Bladder Cancer trials Research Report on Non-muscle Invasive Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| Feasibility of HISA During TURBT for NMIBC HISA - Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) | Not applicable | Not yet recruiting | CAMC Health System | 40 | 2026-08-15 | 2026-09-14 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) Non-Muscle Invasive Bladder Cancer, NMIBC | Recruiting | Natera, Inc. | 400 | 2026-07-27 | 2026-08-13 | |
| Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study Radiation therapy - Non-Muscle Invasive Bladder Cancer | Not applicable | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 50 | 2026-07-23 | 2026-09-11 |
| Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy Bladder Cancer, Non-muscle Invasive Bladder Cancer | Recruiting | Photocure | 500 | 2026-03-25 | 2026-09-04 | |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer PF-08052667, Sasanlimab, BCG - Non-muscle Invasive Bladder Cancer | Phase 1 | Recruiting | Pfizer | 294 | 2025-11-06 | 2026-10-13 |
| A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC) Eciskafusp Alfa, BCG Medac Strain - Non-muscle Invasive Bladder Cancer | Phase 1 | Withdrawn | Hoffmann-La Roche | 2025-06-15 | 2025-06-16 | |
| Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer Mitomycin c - Non-Muscle Invasive Bladder Cancer | Phase 4 | Recruiting | Jakob Kristian Jakobsen | 272 | 2025-06-01 | 2025-10-03 |
| A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) Nadofaragene Firadenovec, Gemcitabine, Docetaxel - Non-Muscle Invasive Bladder Cancer | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 125 | 2025-04-11 | 2026-08-20 |
| The Role of Universal Cancer Only Marker SIX6 in Diagnosing Non-Muscle Invasive Bladder Cancer SIX6 Gene Methylation Assay - Non-muscle Invasive Bladder Cancer | Not applicable | Active not recruiting | Xijing Hospital | 177 | 2025-03-18 | 2026-09-04 |
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer Durvalumab, Monalizumab - Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | John Sfakianos | 60 | 2025-02-24 | 2026-10-05 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 32 | 2024-12-20 | 2026-10-15 |
| A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer Hydeal Cyst® - Non-muscle Invasive Bladder Cancer | Not applicable | Recruiting | Istituto Oncologico Veneto IRCCS | 200 | 2024-12-20 | 2026-08-04 |
| A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer Recombinant oncolytic adenovirus injection solution of VT-101 - Non-muscle Invasive Bladder Cancer | Phase 1 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 16 | 2024-09-18 | 2024-10-09 |
| Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder Tumor En Bloc Transurethral Resection of Bladder Tumor, Conventional Transurethral Resection of Bladder Tumor - Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer | Not applicable | Completed | Lahore General Hospital | 116 | 2024-09-01 | 2026-01-16 |
| Study of CG0070 After Transurethral Resection in Patients With IR NMIBC CG0070 - Non-muscle Invasive Bladder Cancer | Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2024-03-01 | 2026-07-02 |
| Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC) BCG for Therapeutic Use - Non-Muscle Invasive Bladder Cancer | Phase 3 | Unknown | Chengdu CoenBiotech Co., Ltd | 412 | 2023-12-28 | 2024-02-05 |
| Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer Disitamab vedotin, Bacillus Calmette Guerin Vaccine - Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression | Phase 2 | Active not recruiting | Fudan University | 20 | 2023-12-18 | 2026-07-20 |
| Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC) CxBladder Monitor, Cystoscopy - Non-muscle Invasive Bladder Cancer | Completed | Mayo Clinic | 107 | 2023-11-16 | 2026-01-23 | |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer TARA-002 - Non-muscle Invasive Bladder Cancer | Phase 2 | Recruiting | Protara Therapeutics | 131 | 2023-09-15 | 2026-08-24 |
Showing 20 of 57. Sign in to see all of them.
Non-Muscle Invasive Bladder Neoplasms (57) · Urinary Bladder Neoplasms (24) · Carcinoma in Situ (7) · Recurrence (7) · Carcinoma, Transitional Cell (6) · Neoplasms (5) · Urinary Bladder Diseases (3) · Urogenital Neoplasms (3) · Urologic Diseases (3) · Urologic Neoplasms (3) · Disease Progression (2) · Neoplasms by Site (2) · Disease (1) · Smoking (1)
Carcinoma (57) · Female Urogenital Diseases (57) · Female Urogenital Diseases and Pregnancy Complications (57) · Male Urogenital Diseases (57) · Neoplasms by Histologic Type (57) · Neoplasms, Glandular and Epithelial (57) · Urogenital Diseases (57) · Neoplasms by Site (55) · Urinary Bladder Diseases (54) · Urogenital Neoplasms (54) · Urologic Diseases (54) · Urologic Neoplasms (54) · Neoplasms (52) · Urinary Bladder Neoplasms (33) · Pathologic Processes (8)
Gemcitabine (4) · BCG Vaccine (3) · Epirubicin (3) · Mitomycin (3) · Docetaxel (2) · disitamab vedotin (2) · ALT-801 (1) · ALT-803 (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Cystoscopy (1) · Imiquimod (1) · Laser Therapy (1) · Nonsteroidal Anti-Androgens (1) · Radiotherapy (1)
Jiangsu Yahong Meditech Co., Ltd aka Asieris (3) · Jørgen Bjerggaard Jensen (3) · Mansoura University (3) · Protara Therapeutics (3) · Memorial Sloan Kettering Cancer Center (2) · Pfizer (2) · Aarhus University Hospital (1) · Altor BioScience (1) · Astellas Pharma Global Development, Inc. (1) · Bakirkoy Dr. Sadi Konuk Research and Training Hospital (1) · BioCis Pharma Ltd (1) · CAMC Health System (1) · CG Oncology, Inc. (1) · CHU de Quebec-Universite Laval (1) · Chengdu CoenBiotech Co., Ltd (1)
United States (27) · China (10) · Canada (7) · Spain (7) · United Kingdom (6) · Denmark (5) · France (5) · Italy (5) · Germany (4) · Australia (3) · Belgium (3) · Egypt (3) · Norway (3) · Poland (3) · South Korea (3)
Ahmed A. Shokeir (2) · Ahmed Elkashef (2) · Dingwei Ye, MD,PhD (2) · Ahmed Mosbah (1) · Armine Smith, MD (1) · Bernard Bochner, MD (1) · Bobby Reddy, MD (1) · Christine Tosone, Ms, RAC (1) · Dingwei Ye (1) · Dingwei Ye, PI (1) · Eugene Pietzak, MD (1)
PMID 15586136, PMID 20855414, PMID 23088985, PMID 26014293, PMID 26879805, PMID 28712033, PMID 28755959, PMID 28886381, PMID 28981385, PMID 31273010, PMID 32615118, PMID 33924556, PMID 34103518, PMID 35818122, PMID 37980511, PMID 38189180, PMID 38553868, PMID 38953850, PMID 39035212, PMID 39928162, PMID 40450141, PMID 41397208, PMID 42008114, PMID 42177753, PMID 42337683
2023 (2), 2009 (1), 2014 (1), 2016 (1), R01CA252057 (1), U54GM104942 (1)